NASDAQ: AZN
Astrazeneca Plc Earnings & Revenue

AZN past earnings growth

How has AZN's earnings growth performed historically?
Company
-4.65%
Industry
10.68%
Market
82.89%
AZN's earnings have grown faster (11.77% per year) than the US Drug Manufacturers - General industry average (8.89%)
Performance
AZN's earnings have grown slower (11.77% per year) than the US market average (77.34%)
Performance
AZN's earnings growth is slowing down - its growth over the last year (-4.65%) is below its 5-year compound annual rate (11.77%)
Performance

AZN past revenue growth

How has AZN's revenue growth performed historically?
Company
11.39%
Industry
6.62%
Market
16.55%
AZN's revenue has grown slower (0.01% per year) than the US Drug Manufacturers - General industry average (4.07%)
Performance
AZN's revenue has grown slower (0.01% per year) than the US market average (15.67%)
Performance
AZN's revenue growth is accelerating - its growth over the last year (11.39%) is above its 5-year compound annual rate (0.01%)
Performance

AZN earnings and revenue history

Current Revenue
$25.7B
Current Earnings
$2.0B
Current Profit Margin
8%
AZN's has not demonstrated consistent long-term earnings growth over the past 10 years (-72.2%)
Performance

AZN Return on equity

Current Company
16.9%
Current Industry
10.9%
Current Market
-36.3%
AZN's Return on Equity (16.9%) shows a company that is not efficient at transforming shareholder equity into returns
Performance

AZN Return on assets

Current Company
3.4%
Current Industry
8.5%
Current Market
6.2%
AZN is generating lower Return on Assets (3.4%) than the US Drug Manufacturers - General industry average (8.27%)
Performance

AZN Return on capital employed

Current Company
9.37%
Current Industry
12.8%
AZN's ability to generate Return on Capital (9.37%) has decreased compared to 3 years ago (10.99%)
Performance

Astrazeneca Earnings & Revenue FAQ

On Feb 14, 2020, Astrazeneca (NASDAQ: AZN) reported Q4 2019 earnings per share (EPS) of $0.12, up 70.73% year over year. Total Astrazeneca earnings for the quarter were $277.00 million. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.41.
On Feb 14, 2020, Astrazeneca (NASDAQ: AZN) reported Q4 2019 revenue of $6.66 billion up 3.85% year over year. In the same quarter last year, Astrazeneca's revenue was $6.42 billion.
As of Q4 2020, Astrazeneca's earnings has grown -4.65% year over year. This is 15.33 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 10.68%. Astrazeneca's earnings in the past year totalled $2.05 billion.
As of Q4 2020, Astrazeneca's revenue has grown 11.39% year over year. This is 4.77 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 6.62%. Astrazeneca's revenue in the past year totalled $25.70 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics